title: [High frequency of cutaneous adverse effects under infliximab. Geneva experience, 1999-2008].
abstract: Geneva experience, 1999-2008 Infliximab has been used for 10 years in the treatment of chronic inflammatory bowel diseases in the gastroenterology and hepatology department at the University Hospitals of Geneva. This retrospective study shows the follow-up of these patients treated with infliximab and reveals a high rate of cutaneous adverse events, which, although often mild, can sign a definitive intolerance to treatment.
authors.affiliation: Service de médecine interne, Hôpital de Nyon, Chemin Monastier 10, 1260 Nyon. floriane.seydtaghia@ghol.ch
authors.forename: Floriane
authors.initials: F
authors.lastname: Seydtaghia
authors.forename: Philippe
authors.initials: P
authors.lastname: De Saussure
authors.forename: Antoine
authors.initials: A
authors.lastname: Hadengue
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013557:Switzerland; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab